Registries for Irritable Bowel Syndrome (IBS) Research Volunteers Created in the United Kingdom and Australia

September 30, 2017

In recent weeks, IBS Impact has learned that two separate entities, the County Durham and Darlington NHS Foundation Trust in the United Kingdom, and Macquarie University Faculties of Human Sciences and Medicine and Health Sciences in Sydney, Australia have established new, secure registries for those who are interested in volunteering for research studies.

The Macquarie registry is for all adults with any functional gastrointestinal disorder  IBS is the most common FGID. Information can be found here.  Macquarie University Functional Gastrointestinal Disorder Research Volunteer Registry.

The County Durham and Darlington NHS Foundation Trust registry is specific to IBS and is also limited to adults at this time. According to a September 29, 2017 announcement on the NHS National Institute of Health Research site.  it is part of a five year study to encourage those with IBS to be aware of and seek care and to increase participation in clinical trials. If the registry succeeds, the hope is to expand it nationwide in the future. The official website for the service, to be known as Contact ME-IBS, is linked here.

In each case, placing one’s name and contact details on the registry does not guarantee that one will be contacted or be eligible for any specific research study, as requirements for volunteers vary with each individual study. Similarly, there is no obligation to participate in a specific study if contacted. It is simply an expression of possible future interest, allowing researchers to be aware of and efficiently reach out to potential participants willing to be recruited within the IBS/functional GI disorders community.

IBS Impact welcomes researchers affiliated with academic, medical or pharmaceutical entities, or reputable organizations representing IBS or related or commonly overlapping conditions, to contact us directly with additional registries, studies or surveys they wish to be considered for posting. A contact form is available on the main IBS Impact website.

IBS Impact makes these announcements available for general information, and encourages its members and site visitors to make their own individual, informed choices about their potential participation. Additional studies can be found by clicking on the Research– Clinical Trials sub-category in the right sidebar of this blog on our main website IBS studies page. Please be sure to check the date at the top or bottom of a given post, as many posts from this blog remain visible in search engines for several years, and studies stop accepting volunteers or conclude the trials after a period of time. IBS Impact, as an entity, is not directly affiliated with any research sponsor or organization and receives no funding from any source for studies, surveys or links we feature on this blog, the main site or social media.


Representative Hastings of Florida Co-Sponsors HR 1187 for Functional Gastrointestinal and Motility Disorders

July 14, 2017

According to IFFGD and the official Congressional legislative database Congress.gov, Representative Alcee Hastings (D-FL-20) signed on yesterday as a co-sponsor of of the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2017.

Representative Hastings is serving his thirteenth term in the House of Representatives. His current district, the 20th Congressional District of Florida, encompasses parts of Broward and Palm Beach Counties, including parts of Miramar, Fort Lauderdale, and West Palm Beach.  Representative Hastings has a long record of supporting a wide range of health issues and is currently a member of the Congressional caucuses for numerous other specific chronic medical conditions and disabilities as seen on his official house website.

In officially supporting HR 1187, Representative Hastings joins Representative F. James Sensenbrenner, Jr. (R-WI-5), who is the initial sponsor, and co-sponsors, Representatives Mark Pocan (D-WI-2), Eliot Engel (D-NY-16),and Dave Loebsack (D-IA-2)  If you are a constituent of any of these legislators, please take a few minutes to call, write, or contact him on social media to thank him for his  support of the functional gastrointestinal and motility disorders community.

U. S. citizens, if your Member of Congress is not yet a co-sponsor of HR 1187, please see the previous post from March 21, 2017 for links to the bill and more details on how to do so.  Often, it takes multiple attempts to elicit any interest from legislators, so if you do not receive a reply, do not hesitate to try again or to switch contact methods until you attract attention. Keep in mind that your Representative may be different from before because of the 2016 elections, district boundaries that may have been re-drawn, or if you have moved.

Your personal experiences as a person with IBS and/or other functional GI/motility disorders, or as a concerned family member, friend or colleague, are most effective in communicating to legislators and their staff that there are real human beings behind the statistics. However, even general expressions of support are helpful.

HR 1187 is bipartisan legislation (supported by members of both parties) and according to IFFGD discussions with IBS Impact,  is “revenue-neutral,” meaning that there will be no additional taxes or spending added to the current federal deficit if it is enacted. Discretionary funds are available at the National Institutes of Health to be allocated if Congress directs NIH, through this Act, that functional gastrointestinal and motility disorders are a priority. Congress will only do so if we, as a community, are able to show them the importance of the research, education and FDA coordination provided for in HR 1187.

NIH grants funding to researchers throughout the world, not just in the U.S., so in the long run, enactment of this Act may also benefit readers with IBS in other countries. Medical research also sometimes involves multinational teams of scientists, and in any case, study results are usually published globally, adding to the cumulative knowledge worldwide.

It is IBS Impact’s understanding that HR 1187 will not require a debate or vote on the floor of the House of Representatives, and will pass as soon as it reaches 218 sponsor/cosponsors, or a simple majority of the House. In order for this milestone to be accomplished during the current Congress, the 115th,  the necessary number of sponsor/cosponsors must be reached by December 2018. Every two years, the Congressional membership will be different as a result of elections. Thus, if HR 1187 has not passed by that time,  a similar bill will have to be reintroduced and the FGIMD community will have to start the process of gathering co-sponsors anew. This is what occurred with HR 2239 in 2012, HR 842 in 2014 and HR 2311 in 2016. While it is quite common for legislation of various sorts to take several Congresses to pass, our continuing advocacy now can increase awareness, build momentum and perhaps accelerate passage. It is in our hands.

Check back on this blog or join IBS Impact’s Facebook page or Twitter feed for further updates on HR 1187 as they occur. Links to the social media sites can be found on the right sidebar of the blog.


Representatives Engel of New York and Loebsack of Iowa Co-Sponsor HR 1187 for Functional Gastrointestinal and Motility Disorders

June 28, 2017

According to IFFGD and the official Congressional legislative database Congress.gov, Representative Eliot Engel (D-NY-16) and Representative Dave Loebsack (D-IA-2)  signed on earlier this month as co-sponsors of the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2017.

Representative Engel is serving his sixteenth term in the House of Representatives. His current district, the 16th Congressional District of New York, encompasses the northern portion of the Bronx, which is one of the boroughs of New York City, as well as parts of suburban southern Westchester County. Representative Engel is also a current member of the Subcommittee on Health, where HR 1187 is  under consideration.  See the linked website for a list of all current members. Representative Engel has a long record of supporting  a wide range of veterans’ issues and health issues, as seen on his official house website. As previously discussed on this blog on August 12, 2011 and August 25, 2011, military service members and veterans are at disproportionately high risk for functional gastrointestinal disorders like IBS, which are already very common in the general population.

Representative Loebsack is serving his sixth term in the House of Representatives. His district, the 2nd Congressional District of Iowa encompasses most of the southeastern region of the state including  the cities of Davenport, Iowa City, Clinton  and Ottumwa, among others. According to his official House website, Representative Loebsack is currently a member of the House Energy and Commerce Committee, which includes the Subcommittee on Health. He has immediate family members currently serving in the military, previously served on the House Committee on Armed Services, and also has a strong record of supporting veterans’ issues.

In officially supporting HR 1187, Representatives Engel and Loebsack join Representative F. James Sensenbrenner, Jr. (R-WI-5) , who is the initial sponsor and Mark Pocan (D-WI-2) ,the initial co-sponsor. All of these Representatives also supported the previous version of this Act, HR 2311, in 2015-2016, and Representative Sensenbrenner has been the initial sponsor for all four versions of the Act since 2010. If you are a constituent of any of these legislators, please take a few minutes to call, write or contact him on social media to thank him for his continuing support of the functional gastrointestinal and motility disorders community.

U. S. citizens, if your Member of Congress is not yet a co-sponsor of HR 1187, please see the previous post from March 21, 2017 for links to the bill and more details on how to do so.  Often, it takes multiple attempts to elicit any interest from legislators, so if you do not receive a reply, do not hesitate to try again or to switch contact methods until you attract attention. Keep in mind that your Representative may be different from before because of the 2016 elections, district boundaries that may have been re-drawn, or if you have moved.

Your personal experiences as a person with IBS and/or other functional GI/motility disorders, or as a concerned family member, friend or colleague, are most effective in communicating to legislators and their staff that there are real human beings behind the statistics. However, even general expressions of support are helpful.

HR 1187 is bipartisan legislation (supported by members of both parties) and according to IFFGD discussions with IBS Impact,  is “revenue-neutral,” meaning that there will be no additional taxes or spending added to the current federal deficit if it is enacted. Discretionary funds are available at the National Institutes of Health to be allocated if Congress directs NIH, through this Act, that functional gastrointestinal and motility disorders are a priority. Congress will only do so if we, as a community, are able to show them the importance of the research, education and FDA coordination provided for in HR 1187.

NIH grants funding to researchers throughout the world, not just in the U.S., so in the long run, enactment of this Act may also benefit readers with IBS in other countries. Medical research also sometimes involves multinational teams of scientists, and in any case, study results are usually published globally, adding to the cumulative knowledge worldwide.

It is IBS Impact’s understanding that HR 1187 will not require a debate or vote on the floor of the House of Representatives, and will pass as soon as it reaches 218 sponsor/cosponsors, or a simple majority of the House. In order for this milestone to be accomplished during the current Congress, the 115th,  the necessary number of sponsor/cosponsors must be reached by December 2018. Every two years, the Congressional membership will be different as a result of elections. Thus, if HR 1187 has not passed by that time,  a similar bill will have to be reintroduced and the FGIMD community will have to start the process of gathering co-sponsors anew. This is what occurred with HR 2239 in 2012, HR 842 in 2014 and HR 2311 in 2016. While it is quite common for legislation of various sorts to take several Congresses to pass, our continuing advocacy now can increase awareness, build momentum and perhaps accelerate passage. It is in our hands.

Check back on this blog or join IBS Impact’s Facebook page or Twitter feed for further updates on HR 1187 as they occur. Links to the social media sites can be found on the right sidebar of the blog.


Research Links Gut Microbiome Changes to Brain Structure in Irritable Bowel Syndrome (IBS)

June 14, 2017

The international gastroenterology conference, Digestive Disease Week, which traditionally takes place annually in mid-to-late May or early June generally brings a wealth of news on state of the science developments in gastroenterology research for a range of conditions, including irritable bowel syndrome (IBS). One of the interesting and groundbreaking articles presented this year,  which has received recent coverage in both scientific and mainstream media, is a collaboration of 14 researchers from UCLA, Texas Children’s Microbiome Center and Baylor College of Medicine,  and the Washington University School of Medicine in St, Louis, Missouri. The authors confirmed the existence of IBS microbiome subgroups as found in various researchers’ past work and made a preliminary identification of some specific microbes and their metabolites that appear to be involved. Also, for the first time, they found that structural differences in the brains of some study volunteers with IBS appear to correlate with gut microbiome composition.

The open access full text of the journal article, “Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome” by J. S. Labus, et al, was published in  Microbiome on May 1, 2017 and is linked above. “Study shows association between gut microbes and brain structure in people with IBS” by Enrique Rivero of the medical news website Medical XPress was published on May 5, 2017 based on information from UCLA. These sources were consulted for the summary below.

International IBS research in past years has previously established that IBS involves disruptions in the brain-gut-microbiome axis in both directions from the brain to the lower GI tract and from the GI tract to the brain. It also has been known that there are structural and functional brain changes in IBS, particularly in the areas controlling sensation and salience (a mechanism of the brain involved in attention to and perception of the relevance of stimuli), and particularly in those with a history of early trauma. Additionally, it has been known that there are changes in microbiome composition in those with IBS compared to healthy controls. However, until now, because of the extremely large number and range of different types of microbes present in the GI tract, it has been challenging to pinpoint specific and consistent microbes or to connect these patterns to the neurological differences. The above study has begun to do so.

The investigators obtained a variety of data from the volunteers including, history, physical exam, numerous standard questionnaires for various aspects of mental health, behavior, diet, and trauma history, if any,  as well as stool samples and brain imaging. The study participants included 29 adults with IBS according to Rome III international diagnostic criteria (in effect at the time, although Rome IV has been in effect since May 2016), about three-quarters of whom were female, representing all of the bowel habit subtypes, diarrhea, constipation, alternating or mixed, and unspecified/unsubtyped. There were 23 control subjects without IBS, all of whom were female. The IBS and control groups were roughly similar in average age. The average length of having IBS for those in the IBS group was 11.3 years, plus or minus 13.2 years.

There were no statistically significant differences in diet. Although a minority of the IBS group showed clinical anxiety and the total trauma history scores were similar between the two groups, those with IBS reported greater anxiety, stress, catastrophizing and trauma history.

The microbiome analyses showed that the participants with IBS fell into two groups. 14 individuals (9 women, 5 men) had a statistically significant altered gut microbiomes while the other 15 (12 women, 3 men) had microbiomes that were essentially indistinguishable from the healthy controls. These differences between groups were not correlated with age, IBS subtype, medication usage, stress, anxiety, depression or catastrophizing. There was some association between history of early life adversity and length of time with IBS and the microbiome alterations in the first group.  Neurological changes in relation to the healthy control group were found in both subgroups of the volunteers with IBS, but were more pronounced and extensive in the group with the microbiome changes.

It should be emphasized that this was a preliminary, exploratory study of a relatively small sample group, and while many details of the findings appeared to the researchers to be consistent with past studies on IBS , some aspects were more surprising, and many unknowns remain, including the causes of these alterations in these individuals with IBS. However, it is hoped that in time, with further research, IBS investigators will be able to identify consistent microbiome patterns in particular subgroups of IBS that will aid in diagnosis and determination of the optimal treatments for  specific individuals.

IBS Impact looks forward to following the progress of research in this aspect of IBS and hopes to report on more advances in the months and years to come.

 


Representative Pocan of Wisconsin Co-Sponsors HR 1187 for Functional Gastrointestinal and Motility Disorders

May 8, 2017

According to IFFGD and the official Congressional legislative database Congress.gov, Representative Mark Pocan (D-WI-2) recently signed on as the first co-sponsor to the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2017.

Representative Pocan is serving his third term in the House of Representatives. His district, the 2nd Congressional District of Wisconsin, encompasses Dane County, Iowa County, Lafayette County, Sauk County and Green County and parts of Richland and Rock Counties, including the state capital of Madison and environs. According to his official House website, Representative Pocan is a member of the House Appropriations Committee where he sits on the Subcommittee on Labor, Health and Human Services and Education, and he supports various health and veterans’ issues. Functional gastrointestinal disorders like IBS disproportionately affect military veterans and service members. He was also a co-sponsor of the most recent previous version of the Act, HR 2311 in 2015-2016, which did not pass.

If you are a constituent of Representative Pocan, please take a few minutes to write or call him with your thanks for his continued  support of the functional gastrointestinal and motility disorders community.

In officially supporting HR 1187, Representative Pocan joins Representative F. James Sensenbrenner, Jr. (R-WI-5) , who is the initial sponsor. If you are a constituent of Representative Sensenbrenner, please thank him as well.

U. S. citizens, if your Member of Congress is not yet a co-sponsor of HR 1187, please see the previous post from March 21, 2017 for links to the bill and more details on how to do so.  Often, it takes multiple attempts to elicit any interest from legislators, so if you do not receive a reply, do not hesitate to try again or to switch contact methods until you attract attention. Keep in mind that your Representative may be different from before because of the 2016 elections, district boundaries that may have been re-drawn, or if you have moved.

Your personal experiences as a person with IBS and/or other functional GI/motility disorders, or as a concerned family member, friend or colleague, are most effective in communicating to legislators and their staff that there are real human beings behind the statistics. However, even general expressions of support are helpful.

HR 1187 is bipartisan legislation (supported by members of both parties) and according to IFFGD discussions with IBS Impact,  is “revenue-neutral,” meaning that there will be no additional taxes or spending added to the current federal deficit if it is enacted. Discretionary funds are available at the National Institutes of Health to be allocated if Congress directs NIH, through this Act, that functional gastrointestinal and motility disorders are a priority. Congress will only do so if we, as a community, are able to show them the importance of the research, education and FDA coordination provided for in HR 1187.

NIH grants funding to researchers throughout the world, not just in the U.S., so in the long run, enactment of this Act may also benefit readers with IBS in other countries. Medical research also sometimes involves multinational teams of scientists, and in any case, study results are usually published globally, adding to the cumulative knowledge worldwide.

It is IBS Impact’s understanding that HR 1187 will not require a debate or vote on the floor of the House of Representatives, and will pass as soon as it reaches 218 sponsor/cosponsors, or a simple majority of the House. In order for this milestone to be accomplished during the current Congress, the 115th,  the necessary number of sponsor/cosponsors must be reached by December 2018. Every two years, the Congressional membership will be different as a result of elections. Thus, if HR 1187 has not passed by that time,  a similar bill will have to be reintroduced and the FGIMD community will have to start the process of gathering co-sponsors anew. This is what occurred with HR 2239 in 2012, HR 842 in 2014 and HR 2311 in 2016. While it is quite common for legislation of various sorts to take several Congresses to pass, our continuing advocacy now can increase awareness, build momentum and perhaps accelerate passage. It is in our hands.

Check back on this blog or join IBS Impact’s Facebook page or Twitter feed for further updates on HR 1187 as they occur. Links to the social media sites can be found on the right sidebar of the blog.


IBS Awareness Month 2017: Approaching a Decade of IBS.

April 30, 2017

by Nina Pan, IBS Impact founder and primary blogger for IBS Impact.

Four years ago, on April 24, 2013, I wrote a post for IBS Awareness Month that began with some reflections on my personal experiences with IBS, as well as my motivations for IBS Impact. At that time, I had been living with IBS for over five years, and 2013 marked my sixth April with IBS. I observed how for many of us, dealing with the numerous actual or potential effects on a day to day basis often makes it difficult to recognize when progress is being made, either for us as individuals, or for the IBS community as a whole. I stated that it is only with the passage of time that I had begun to realize how some things are indeed changing, albeit slowly, for the better. In the rest of the post, I pointed out numerous areas in IBS research, IBS treatment, understanding of the impact of IBS on quality of life, increased societal support and advocacy that had seen concrete, positive change in just the five years and six IBS Awareness Months I had personally experienced.

 On April 10, 2014 ,  April  14, 2015, and April 29, 2016, I reported in a similar vein on progress for the IBS community in each respective year. Now, continuing the tradition during my own ninth year and tenth IBS Awareness Month, once again, I can observe small steps forward in just a single year.

Progress in the science of IBS:

In the past year, the science of IBS has continued to expand in many areas, from diet, to gut microbiota, to understanding of the visceral hypersensitivity responsible for pain, to stigma, and the effect of parental response on children with functional abdominal pain  and many other topics. These varied endeavors are taking place in or with the involvement of many scientists from many countries. See other posts in the Research category of the blog sidebar or our Facebook or Twitter feeds to see the range of research news and clinical trial opportunities publicized over the most recent several months. The annual Digestive Disease Week international gastroenterology conference taking place shortly in May traditionally provides even more state of the science research news each year.

Progress in the diagnosis and treatment of IBS:

 Over the past two and a half years, this blog has often reported on the development of Rome IV criteria, the latest update to the international symptom-based diagnostic criteria for functional gastrointestinal disorders like IBS, which was officially published and presented to the international gastroenterology community in May 2016.  This latest update reportedly involved over 100 experts from numerous countries. The Rome criteria, which are said by leading IBS researchers to be 98% accurate for most people with IBS symptoms, have been in existence in some form for 26 years, although research shows that many people with IBS and medical professionals who do not specialize in IBS remain unaware of this.

In addition to some changes in symptom criteria, Update on Rome Criteria for Colorectal Disorders: Implications for Clinical Practice,” by Magnus Simren, MD of the University of Gothenburg in Sweden, Olafur Palsson, PsyD and William Whitehead, PhD of the University of North Carolina Center for Functional GI and Motility Disorders in the U.S., published this month in Current Gastroenterology Reports, notes that the Rome IV is attempting to encourage a transition from the more stigmatizing “functional GI disorders” to a “disorders of gut-brain interaction,” which is more reflective of current understanding of IBS and related disorders, some of which include functional diarrhea, functional constipation and  centrally mediated abdominal pain (functional/recurrent abdominal pain) among others affecting the lower or upper GI tract.  In addition, the authors state that, “Therefore, in Rome IV it is emphasized that functional bowel disorders constitute a spectrum of GI disorders rather than isolated entities. It is acknowledged that, even though they are characterized as distinct disorders based on diagnostic criteria, significant overlap exists, and occasionally, it may be difficult to distinguish them as distinct entities. Furthermore, it is also highlighted that transition from one functional bowel disorder to another, or from one predominant symptom to another, is frequently seen, and this may occur as part of the natural course of the disorder, as a response to therapy, or both.”

As this blog reported on October 11, 2015,  Rome IV guidance also includes a new Multidimensional Clinical Profile which, for the first time, takes into account common extraintestinal (non-GI) symptoms and other psychological and social factors that may influence care. It is hoped that all of these changes will provide better diagnosis and treatment for people with IBS worldwide, and new opportunities for education of medical professionals in disorders of gut-brain interaction.

Several investigational medications and other non-pharmaceutical treatment options are always in the research pipeline in various parts of the world. Eluxadoline (brand name Viberzi), already in use in the United States, was approved by Health Canada in March 2017. According to Canadian contacts, the timeline for availability depends on provincial decisions.

 Progress in understanding the impact of IBS and the barriers that remain:

As this blog reported on January 29, 2017, in December 2016, the Gastrointestinal Society released its report on a year-long survey on experiences and opinions and needs of adults with IBS and parents of children with IBS across Canada. The results are intended to shape future GI Society programs and to advocate and educate health care providers, policymakers and community members about IBS. A five-question followup survey, open to previous and new participants, is still accepting responses at this time. The link to both the report and the follow-up are in the linked January post.

Progress in societal supports for people with IBS:

The IBS Network in the United Kingdom made great progress this past year in its ongoing efforts to support and expand the availability of local, in-person self-help/support groups for people with IBS in the UK. as reported by this blog on October 23, 2016 and January 13, 2017.

Although the Irritable Bowel Information and Support Association (IBIS) in Australia closed this year, the administrators of the IBS Support Facebook group, of which I am one, were pleased to be recognized as one of the two alternative resources IBIS suggested on its remaining web page. This international, evidence-based educational group is currently administered by 9 individuals from 4 countries, all of whom have had IBS for many years, and are highly knowledgeable from formal professional education and experience and/or many years active in the IBS community. At this time, membership is over 27,000 and grows by about 1000 members each month.

Monash University in Australia, developers of the low-FODMAP diet that is effective for reducing symptoms for many people with IBS, continues to test specific foods and product brands in several countries, in some cases, leading to revision of its previous recommendations.  It also adds new countries as research and resources permit. In late March of this year, Dutch foods were added to the app, allowing those in the Netherlands to use it more easily. Monash also has a low-FODMAP certification program, whereby food product manufacturers whose products have been tested by Monash as appropriate for the diet, may display an official certification symbol to alert consumers. The number of products currently certified is small, but growing Previously, the only manufacturers listed were in Australia or New Zealand, but there have been recent additions in the U.S. and Canada as well.

Progress in advocacy and awareness:

The International Foundation for Functional Gastrointestinal Disorders has  continued to shepherd the Functional GI and Motility Disorders Research Enhancement Act through its fourth attempt at passage by the U.S. House of Representatives, with the support of IBS Impact and other groups and individuals. After three previous attempts in the three previous Congresses,  it  was reintroduced in the the current 115th Congress under a different Act number, HR 1187, in March 2017 and has received bipartisan support from Representative.  See the Legislation category, HR 1187,   HR 2311 HR 842 and HR 2239 subcategories in the right sidebar of this blog for more on this history of this important Act.  IFFGD has also been an ongoing advocate for veterans, who are disproportionately at risk for functional gastrointestinal disorders like IBS.

IBS Impact once again completely redesigned and updated its main website in December 2016 and continues to make incremental updates and improvements several times a year.  The number of followers of this blog and our social media accounts continues to increase. Largely due to the release of the Rome IV criteria in May 2016, overall hit counts average 300-400% higher than prior to Rome IV and have remained in the new range almost one year later. A Rome IV post has now displaced the August 12, 2011 post on IBS being added to service-connected disabilities for Gulf-era U.S. veterans as the most popular post in the history of this blog, a status the previous post held from 2011-2015. Cumulatively, IBS Impact now reaches readers in over 130 different countries and territories on every continent of the globe.

These are just a handful of examples of progress for the IBS community in the past year. Cumulatively, there are many more. Obviously, we still have very far to go before all people with IBS have all the medical and social supports that we need for fully productive lives, with or without IBS,  but we have come far as well. There are reasons for hope, especially if more of us do our part for self-advocacy and awareness in the years and IBS Awareness Months to come.


Free Online Webinar for IBS, Functional GI Disorders with Dr. Drossman, “Achieving Effective Patient-Provider Communication” on April 24, 2017

April 17, 2017

The American College of Gastroenterology has announced that for IBS Awareness Month, it will be sponsoring a free online webinar presented by Douglas Drossman, MD, MACG  and one of his patients, Katie Errico on “Achieving Effective Patient-Provider Communication.” The webinar will take place on Monday, April 24, 2017 from 8:00-9:00 p.m. Eastern time. The webinar is designed specifically for people with irritable bowel syndrome and/or other functional gastrointestinal disorders.

Dr. Drossman, a leading, internationally-known expert on IBS, functional gastrointestinal disorders, doctor-patient relationships and the biopsychosocial approach to medical care, is President of the Drossman Center for the Education and Practice of Biospsychosocial Care, President of the Rome Foundation, Professor Emeritus of Medicine and Psychiatry at the University of North Carolina at Chapel Hill, retired co-director of the University of North Carolina Center for Functional GI and Motility Disorders and a longtime board member of the International Foundation for Functional Gastrointestinal Disorders,  along with many other pivotal roles in the development of the field of functional gastrointestinal disorders like IBS over his 40+ year career.

To participate in the webinar, please use the link to register. You will need to provide ACG with your full name and email address so that instructions for accessing the webinar on the scheduled date can be sent to you. It is open to anyone in any geographical location who has Internet access fast enough to handle streaming video, audio and chat technology. You will be able to ask questions after the presentation. Please keep in mind that Dr. Drossman cannot diagnose or treat anyone over the Internet, and depending on the number of participants and questions, he and Ms. Errico may or may not be able to get to every question.

“Achieving Effective Patient-Provider Communication” online webinar with Dr. Drossman, April 24, 2017

This is a tremendous and rare opportunity, especially for people with IBS or their loved ones to hear from and communicate directly with one of the world authorities and pioneers in the research, education and treatment of IBS. IBS Impact thanks ACG for making this webinar possible. We also thank Dr. Drossman for taking time out of his busy schedule to make himself available to the general public, and for his long decades of commitment to making functional gastrointestinal disorders like IBS a serious field of medical research and to supporting and treating many who live with these complex conditions.